Clinical Characteristics and Antimicrobial Resistance Patterns of Pseudomonas Aeruginosa Infections in a Tertiary Hospital in Chongqing: A Retrospective Study from 2021 to 2024
Abstract
Methods: Retrospective analysis was performed on clinical data of a primary hospital in Chongqing from January 2021 to December 2024.
Results: Among the total number of 722 patients (of whom 501 were male and 221 were female with an average age of 63.6 12.4), most
patients displayed increased inflammatory indicators. 124 males (17.2%) had CRP ? 100 mg/L; 251 individuals (34.8%) showed WBC ?
9.5 109 /L; 151 (20.9%) displayed PCT ? 0.5 ?g/L. In patients with pulmonary (n = 195) and otolaryngologic/head neck cancer (n = 150),
infections were seen, and increasing trend by year was seen. The other cases were from gastrointestinal (n=112), hepatobiliary (n=52), and
gynecological (n=48). The antimicrobial susceptibility was still high (?80%) to amikacin(?96.9%), cefe pime, cefepime(ciprofloxacin),
levofloxacin(>80%), meropenem (>80% ), imipenem (>80% ), piperacillin -tazobactam (>80% ), ceftazidime. Cefoperazone-sulbactam susceptibility: ?70% Aztreonam susceptibility: ?50% After the treatment, 108 patients ( 14.9 %) were better and discharged; 46 ( 6.4 %) died.
Conclusions: P. aeruginosa infection of cancer patient has a tendency to correlate with high levels of inflammatory markers and also co-infection is very common in case of immunocompromised patients. Carbapenem-resistant P. aeruginosa (CRPA) rate 8-15%. Strengthen the use of
antibiotics rationally and slow down the development of resistance.
Keywords
Full Text:
PDFReferences
[1] Azam M W, Khan A U. Updates on the pathogenicity status of Pseudomonas aeruginosa. Drug Discovery Today, 2019, 24(1):350-359.
[2] Thi MTT, Wibowo D, Rehm BHA. Pseudomonas aeruginosa biofilms[J]. Int J Mol Sci, 2020, 21(22):8671-8672.
[3] National Microbial Resistance Surveillance Network. 2014-2019 Surveillance Report on Bacterial Resistance Monitoring [J]. Chinese
Journal of Infection Control, 2021, 20(1):15 30. DOI: 10.12138/j.issn.1671 9638.20216170.
[4] Gellatly SL, Hancock RE. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses[J]. Pathog Dis, 2013, 67(3):159-
173.
[5] Han Ping, Zhao Jianqing, Zhang Wei et al. Analysis of factors affecting carbon penicillin-resistant Pseudomonas aeruginosa nosocomial
infection and prognosis [J]. 2025, 44(3):282-288.
[6] Qin J, Zou C, Tao J, et al. Carbapenem resistant Pseu-domonas aeruginosa infections in elderly patients: antimicrobial resistance profiles, risk factors and impact on clinical outcomes [J]. Infect Drug Resist, 2022, 15:2301-2314.
DOI: http://dx.doi.org/10.70711/pmr.v2i7.7716
Refbacks
- There are currently no refbacks.
